®ADMEcell Enters into an Agreement To Exclusively Distribute RD-Biotech's FastELYSA® product line throughout North America 1/20/2011
Emeryville, Calif., January 20, 2011 ADMEcell, Inc. today announced that it has entered into an exclusive agreement with RD-Biotech, Besancon, France, to distribute the FastELYSA® product line in the North American market.
The FastELYSA® products are a new, innovative Ready-to-Use ELISA kits designed to reduce the time and cost of quantification and isotyping of immunoglobulins in antibody drug development process. The FastELYSA® product line provides an off-the-shelf and user-friendly stand alone kit as well as a solution for high-throughput automated procedures.
RD-Biotech (www.rd-biotech.com) is a leader in providing products, services and reagents for the biotech industry, including Ready-to-Use assay kits. RD-Biotech's business model allows it to achieve substantial reductions in costs, risks and the development time. Their most successful product to date is the FastELYSA® product line, which provides a simple and rapid method for quantification of immunoglobulins concentration in various species as well as isoptyping of the mouse immunoglobulins.
RD-Biotech operates throughout five divisions: molecular biology, which concentrates its activity on development through to clinical concept testing of innovative pharmaceuticals in search for new applications of known molecules; Analytical Testing, which involves sample preparation, analytical service and analytical method development from research through product prototypes; cell culture development and production (primary cells or cell lines); immunology with a focus on in-vitro development and production of monoclonal antibodies; and Ready-to- Use ELISA products from concept to manufacturing.
Licensing and Distribution Opportunities:
ADMEcell, a Bay Area based biotechnology company is currently considering the licensing and/or distribution of unique, state-of-the-art Ready-to-Use kits that have important applications in the drug discovery process. Please contact ADMEcell (email@example.com) in confidence if you have a unique, compelling Ready-to-Use kit that is relevant to the biotechnology and life science marketplace, particularly to ADME-toxicology.
link Press Release / Story ADMEcell Enters into an Agreement to Exclusively Distribute RD-Biotech products Throughout North America. www.admecell.com